1. Elbadawi A, Meyer S. Morphometry of the obstructed detrusor. I. Review of the issues. Neurourol Urodyn 1989;8:163-71.
2. Steers WD, Creedon DJ, Tuttle JB. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol 1996;155:379-85. PMID:
7490891
3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population based survey of urinary incontinence, overactive bladde, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15. PMID:
17049716
5. Apostolidis A, Gonzales GE, Fowler CJ. Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters and quality of life of patients with urodynamic increased bladder sensation. Eur Urol 2006;50:1299-305. PMID:
16697519
6. Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2007;99:85-96. PMID:
17026588
7. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253-6. PMID:
12771763
8. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174:2273-5, discussion 5-6.
9. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004;94:817-20. PMID:
15476515
10. van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in asingle tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomized controlled NEPTUNE trial. Eur Urol 2013;64:1003-12. PMID:
23932438
11. Kaplan S, Roehrborn C, Dmochowski R, Rovner E, Wang J, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006;68:328-32. PMID:
16904446
12. Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009;55:472-81. PMID:
18583022
13. Chapple CR, Herschorn S, Abrams P, Wang JT, Brodsky M, Guan Z. Efficacy and safety of tolterodine extended release in men with overactive bladder symptoms treated with an a-blocker α-blocker: effect of baseline prostate-specific antigen concentration. BJU Int 2010;106:1332-8. PMID:
20497416
14. Sakalis V, Sfiggas V, Vouros I, Salpiggidis G, Papathanasiou A, Apostolidis A. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study. Int J Urol 2018;25:737-45.
15. Abrams P, Cardozo L, Griffiths D, Rosier P. The standardization of terminology in lower urinary tract function: report from the standardization subcommittee of the International Continence Society. Urology 2003;61:37-49. PMID:
12559262
16. Andersson KE. Antimuscarinic mechanisms and overactive detrusor: an update. Eur Urol 2011;59:377-86. PMID:
21168951
17. Finney SM, Andersson KE, Gillerspie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006;98:503-7. PMID:
16925744
18. Stohrer M, Bauer P, Giannetti BM, Richter R, Burgdorfer H, Murtz G. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol int 1991;47:138-43.
19. Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, GarciaHernandez A, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: Results from a phase 2, dose-finding study (Saturn). Eur Urol 2013;64:398-407. PMID:
23537687
20. Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomized, double-blind, dose-rabging, phase 2 study (Symphony). Eur Urol 2015;67:577-88.
21. Mallone-Lee JG, Henshaw DJ, Cumminhs K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinc treatment response. BJU Int 2003;92:415-7. PMID:
12930431
22. Digesu GA, Khular V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003;22:105-8. PMID:
12579626
23. Michelotti GA, Price DT, Schwinn DA. α1-Adrenergic receptor regulation: basic science and clinical implications. Pharmacol Therapeut 2000;88:281-309.
24. De Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C. the evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003;169:535-9. PMID:
12544303
26. Yokoyama O, Yusup A, Oyama N, Aoki Y, Miwa Y, Akino H. Improvements in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rates. J Urol 2007;177:771-5. PMID:
17222679
27. Barendrecht MM, Frazier EP, Vrydag W, Alewijnse AE, Peters SLM, Michel MC. The effect of bladder outlet obstruction on α1-an β-Adrenoceptor expression and function. Neurourol Urodyn 2009;28:349-55. PMID:
19034955
28. Michel MC. β-Adrenergic receptor subtypes in the urinary tract. In: Andersson KE, Michel M, editors. Urinary tract. Berlin; Springer; 2011. p. 307-18.
29. Monica FZ, Bricola AA, Bau FR, Freitas LL, Teixeira SA, Muscara MN, et al. Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity. Br J Pharmacol 2008;153:1659-68.
30. Hampel C, Dolber PC, Smith MP, Savic SL, Thuroff JW, Thor KB, et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002;167:1513-21. PMID:
11832780
31. Homma Y, Yamaguchi O, Hayashi K; Neurogenic Bladder Society Committee. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006;68:560-4. PMID:
16979726
32. Espuna-Pons M, Blasco P, Perez M, Rebollo P. Nocturia in patients with overactive bladder. Arch Esp Urol 2010;63:363-72. PMID:
20587841
34. Sakalis VI, Karavitakis M, Bedretdinova D, Bach T, Ruud JLH, Gacci M, et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European Association of Urology Guidelines Panel for male lower urinary tract symptoms. Eur Urol 2017;72:757-69. PMID:
28666669